vandetanib

epidermal growth factor receptor ; Homo sapiens







155 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
101 20967300 Vandetanib: An overview of its clinical development in NSCLC and other tumors. 2010 Sep 2
102 19088171 An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. 2009 Mar 2
103 19220256 Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. 2009 Jun 1
104 19318229 Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. 2009 Jun 1
105 19319137 Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. 2009 Apr 21 3
106 19332730 Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. 2009 May 20 3
107 19349511 Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. 2009 Apr 4
108 19362942 Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy. 2009 Mar 1
109 19409038 A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. 2009 Apr 1
110 19447868 Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. 2009 May 15 1
111 19491268 Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. 2009 Jun 15 9
112 19512898 Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. 2009 Jul 2
113 19687425 Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. 2009 Aug 2
114 19881951 The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. 2009 Nov 1
115 19946413 DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. 2009 Sep 21 1
116 17393165 Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. 2008 Feb 15
117 18177496 Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. 2008 Jan 4 1
118 18248788 EGFR and VEGFR as potential target for biological therapies in HCC cells. 2008 Apr 18 1
119 18364248 Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. 2008 Jun 28 1
120 18379357 A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. 2008 Apr 2
121 18381602 Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 2008 Sep 1
122 18520295 Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer. 2008 Jun 3
123 18694994 Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. 2008 Aug 15 3
124 18936474 Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. 2008 Nov 20 1
125 21479415 Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. 2008 May-Jun 3
126 17203163 Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. 2007 Feb 4
127 17243944 Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. 2007 Feb 1
128 17272980 Combined targeted therapies in non-small cell lung cancer: a winner strategy? 2007 Mar 1
129 17308046 Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. 2007 Feb 3
130 17414626 Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. 2007 Jun 3
131 17631646 Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. 2007 Nov 1 4
132 17889445 Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. 2007 Dec 1 2
133 17912240 ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein. 2007 Oct 8 1
134 17975157 Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. 2007 Nov 1 1
135 16332356 ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. 2006 Feb 14 1
136 16377413 ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. 2006 Jan 1 3
137 16688779 Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. 2006 Aug 3
138 16721126 Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience. 2006 Jul 1
139 16783964 ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. 2006 2
140 16891475 Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. 2006 Jul 2
141 16937523 Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. 2006 Aug 28 1
142 17136225 Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. 2006 Oct 3
143 17145834 Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. 2006 Dec 1 3
144 17409986 A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. 2006 Nov 2
145 15709198 Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor. 2005 Feb 1 1
146 15867237 A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. 2005 May 1 3
147 15905307 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. 2005 Aug 1
148 15928657 ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. 2005 Jun 3
149 16061883 Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 2005 Aug 1 1
150 14760102 Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 2004 Jan 15 1